Abstract
Fundamental issues in the traditional surveillance of diarrhoeal disease need to be addressed. The limitations of traditional microbiological diagnostic methods often mean that the cause of diarrhoea remains unknown, especially for novel or difficult-to-isolate pathogens. Sequencing samples directly, without isolating pathogens, would address this issue. However, we must ensure that sequencing also captures pathogens that are detectable using current diagnostic methods.
We show that metagenomic and metatranscriptomic approaches can effectively detect nine gastrointestinal pathogens in the UK. Metatranscriptomics shows increased sensitivity of detection for pathogens like Campylobacter, Clostridioides difficile, Cryptosporidium and Giardia, while metagenomics is more effective for detecting pathogens such as Adenovirus, pathogenic Escherichia coli, Salmonella, Shigella, and Yersinia enterocolitica. Certain pathogens were detected by both metagenomic and metatranscriptomic sequencing. Metatranscriptomics gave near-complete genome coverage for Human mastadenovirus F and detected Cryptosporidium via capture of Cryptosporidium parvum virus (CSpV1). A comprehensive transcriptomic profile of Salmonella Enteritidis was recovered from the stool of a patient with a laboratory-confirmed Salmonella infection.
This study highlights the power of direct sequencing of human samples to augment GI pathogen surveillance and clinical diagnostics. Metatranscriptomics was best for capturing a wide breadth of pathogens and was more sensitive for this purpose. We propose that metatranscriptomics should be considered for future surveillance of gastrointestinal pathogens. This study has generated a rich data resource of paired metagenomic and metatranscriptomic datasets, direct from over 1000 patient stool samples. We have made these data publicly available to promote the improved understanding of pathogens associated with infectious intestinal diseases.
Competing Interest Statement
M.I.G. has received research grants from GSK and Merck, and has provided expert advice to GSK. M.I.G. has been an employee of GSK since January 2023, although the work presented here was completed prior to this date.
Funding Statement
This publication presents independent research supported by the Health Innovation Challenge Fund (WT096200, HICF-T5-354), a parallel funding partnership between the Department of Health and Wellcome Trust. The views expressed in this publication are those of the author(s) and not necessarily those of the Department of Health or Wellcome Trust. This study is also funded by the National Institute for Health Research (NIHR) Health Protection Research Unit in Gastrointestinal Infections at University of Liverpool, in partnership with the UK Health Security Agency (UKHSA), in collaboration with University of Warwick. E.C.-O., N.A.C. and A.C.D. are based at The University of Liverpool. The views expressed are those of the author(s) and not necessarily those of the NIHR, the Department of Health and Social Care or the UK Health Security Agency. N.A.C. is a NIHR Senior Investigator (NIHR203756).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The project commenced on April 1, 2013. The North West - Greater Manchester East Research Ethics Committee (REC reference: 15/NW/0233) and NHS Health Research Authority (HRA) Confidential Advisory Group (CAG) (CAG reference: 15/CAG/0131) approved the INTEGRATE project. Approval was also granted by NHS Research Management and Governance Committees (including Royal Liverpool and Broadgreen University Hospital Trust, Lancashire Teaching Hospitals NHS Foundation Trust, Central Manchester University Hospitals NHS Foundation Trust and the University of Liverpool Sponsor), the Lancaster University Faculty of Health and Medicine Ethics Committee and the University of Liverpool Ethics Sub-Committees. An Information Governance Toolkit (IGT), from the Department of Health hosted by the Health and Social Care Information Centre (HSCIC) was also completed for the project, and all project research staff obtained Honorary NHS contracts, research passports and letters of access, as necessary. The first patient was recruited on October 13, 2015, with 1,407 patients recruited and samples processed using traditional laboratory techniques as of March 2017. All patient participants provided signed, informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The manuscript has been updated to include more perspectives on organism biology. Additional genomic analysis has been conducted in relation to surveillance for Adenovirus and Cryptosporidium. Supplementary materials for the aforementioned analysis have been provided, along with additional information regarding the surveillance methods used by reference laboratories.
Data Availability
Outputs from our analyses are available within the supplementary material of this manuscript. Illumina sequence reads with human data removed have been deposited in the European Nucleotide Archive (ENA) under ENA project accession number PRJEB62473.
